# Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease

> **NCT03909646** · PHASE4 · COMPLETED · sponsor: **Maastricht University Medical Center** · enrollment: 250 (actual)

## Conditions studied

- Bowen's Disease

## Interventions

- **DRUG:** Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram
- **DRUG:** 5Fluorouracil
- **OTHER:** Surgical excision

## Key facts

- **NCT ID:** NCT03909646
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-27
- **Primary completion:** 2022-03-02
- **Final completion:** 2024-12-12
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03909646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03909646, "Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03909646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*